Omeros Corp (OMER):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Omeros Corp (OMER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9800
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Omeros Corp (Omeros) is a biopharmaceutical company that discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company’s pipeline products include Omidria, a phenylephrine and ketorolac injection for use during cataract surgery or replacement of intraocular lens (IOL). The company is investigating its product candidates for use in arthroscopic, ophthalmological, and other surgical procedures including thrombotic microangiopathies, mediated glomerulopathies, addictive and compulsive disorders, among others. It is also evaluating preclinical product candidates for treatment of alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.

Omeros Corp (OMER) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Omeros Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Omeros Corp, Medical Devices Deals, 2012 to YTD 2018 9
Omeros Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Omeros Corp, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Omeros Acquires Antibody Related Assets from Xori 11
Licensing Agreements 12
Omeros Enters into Licensing Agreement with Fagron 12
Equity Offering 13
Omeros Raises USD68.3 Million in Public Offering of Shares 13
Omeros Raises USD0.74 Million in Public Offering of Shares 15
Omeros Raises USD37.3 Million in Public Offering of Shares 16
Omeros Raises USD84 Million in Public Offering of Shares and Pre-Funded Warrants 18
Omeros Completes Public Offering Of Shares For US$40.3 Million 20
Omeros Completes Private Placement Of Common Stock For US$16 Million 22
Omeros Announces Public Offering Of Common Stock For US$60 Million 24
Omeros Completes Public Offering Of Common Stock For US$34.5 Million 25
Omeros Corp – Key Competitors 27
Omeros Corp – Key Employees 28
Omeros Corp – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 09, 2018: Omeros reports second quarter 2018 financial results 30
May 10, 2018: Omeros Reports First Quarter 2018 Financial Results 33
Mar 01, 2018: Omeros Reports Fourth Quarter and Year-End 2017 Financial Results 35
Nov 09, 2017: Omeros Reports Third Quarter 2017 Financial Results 37
Aug 08, 2017: Omeros Reports Second Quarter 2017 Financial Results 39
May 10, 2017: Omeros Reports First Quarter 2017 Financial Results 41
Mar 16, 2017: Omeros Reports Fourth Quarter and Year-End 2016 Financial Results 43
Other Significant Developments 45
Apr 11, 2018: Omeros Announces Amendment of Credit Facility 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Omeros Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Omeros Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Omeros Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Omeros Corp, Medical Devices Deals, 2012 to YTD 2018 9
Omeros Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Omeros Acquires Antibody Related Assets from Xori 11
Omeros Enters into Licensing Agreement with Fagron 12
Omeros Raises USD68.3 Million in Public Offering of Shares 13
Omeros Raises USD0.74 Million in Public Offering of Shares 15
Omeros Raises USD37.3 Million in Public Offering of Shares 16
Omeros Raises USD84 Million in Public Offering of Shares and Pre-Funded Warrants 18
Omeros Completes Public Offering Of Shares For US$40.3 Million 20
Omeros Completes Private Placement Of Common Stock For US$16 Million 22
Omeros Announces Public Offering Of Common Stock For US$60 Million 24
Omeros Completes Public Offering Of Common Stock For US$34.5 Million 25
Omeros Corp, Key Competitors 27
Omeros Corp, Key Employees 28
Omeros Corp, Subsidiaries 29

List of Figures
Omeros Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Omeros Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Omeros Corp, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Omeros Corp (OMER):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kimco Realty Corp (KIM):企業の財務・戦略的SWOT分析
    Kimco Realty Corp (KIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Marksmen Energy Inc (MAH):企業の財務・戦略的SWOT分析
    Summary Marksmen Energy Inc (Marksmen Energy), formerly Marksmen Resources Ltd is an oil and gas exploration and development company that explores and develops light oil assets in Ohio. The company acquires, explores, operates, mines, manages, produces and develops oil and gas properties in Western …
  • Teijin Ltd (3401):製薬・医療:M&Aディール及び事業提携情報
    Summary Teijin Ltd (Teijin) is a technology driven holding company offering solutions in the areas of information and electronics, healthcare, environment and energy and safety and protection. It focuses on the manufacture and sale of aramid fiber, carbon fiber products, synthetic fiber, films, poly …
  • Wayne State University:製薬・医療:M&Aディール及び事業提携情報
    Summary Wayne State University (WSU) is a public research university that offers academic and certificate programs for graduates and undergraduates. The university offers academic programs such as business, engineering, information science, arts and sciences, law, medicine, nursing and health scienc …
  • ClearStream Energy Services Inc:企業の戦略・SWOT・財務情報
    ClearStream Energy Services Inc - Strategy, SWOT and Corporate Finance Report Summary ClearStream Energy Services Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • ICF International Inc (ICFI):企業の財務・戦略的SWOT分析
    ICF International Inc (ICFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Indra Sistemas, S.A.:企業の戦略・SWOT・財務分析
    Indra Sistemas, S.A. - Strategy, SWOT and Corporate Finance Report Summary Indra Sistemas, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • SymBio Pharmaceuticals Ltd (4582):製薬・医療:M&Aディール及び事業提携情報
    Summary SymBio Pharmaceuticals Ltd (SymBio) is a biopharmaceutical company that develops and markets anti-cancer drug candidates. The company develops SyB drugs, treakisym and rigosertib, among others. It offers business development services in areas of oncology, hematology and pain-management areas …
  • Bechtel Power Corporation:企業の戦略的SWOT分析
    Bechtel Power Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Union Investment Group:企業の戦略・SWOT・財務情報
    Union Investment Group - Strategy, SWOT and Corporate Finance Report Summary Union Investment Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Equinix Inc (EQIX):企業の財務・戦略的SWOT分析
    Equinix Inc (EQIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Nichirei Corp (2871):企業の財務・戦略的SWOT分析
    Nichirei Corp (2871) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Lloyds Banking Group Plc:戦略・SWOT・企業財務分析
    Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report Summary Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Egalet Corp (EGLT):製薬・医療:M&Aディール及び事業提携情報
    Summary Egalet Corp (Egalet) is a specialty pharmaceutical company that develops, manufactures and commercializes novel treatments for pain and other conditions. Its product portfolio includes OXAYDO (oxycodone HCl, USP) tablets CII for the management of acute and chronic moderate to severe pain; SP …
  • Banco Cooperativo Espanol S.A.:企業の戦略・SWOT・財務分析
    Banco Cooperativo Espanol S.A. - Strategy, SWOT and Corporate Finance Report Summary Banco Cooperativo Espanol S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • IDT Australia Ltd (IDT)-製薬・医療分野:企業M&A・提携分析
    Summary IDT Australia Ltd (IDT) is a contract manufacturing company that specializes in the development, scale-up and production of active pharmaceutical ingredients (APIs), microbiological and analytical testing, clinical trial research services and pharmacy services. The company also specializes i …
  • Invacare Corporation (IVC):医療機器:M&Aディール及び事業提携情報
    Summary Invacare Corporation (Invacare) is a medical equipment company which develops, manufactures and distributes healthcare products for non-acute care, such as the home healthcare and long term care markets. The major products include power wheelchairs, custom manual wheelchairs, personal mobili …
  • TEGNA Inc (TGNA):企業の財務・戦略的SWOT分析
    TEGNA Inc (TGNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Topdanmark AS (TOP):企業の財務・戦略的SWOT分析
    Topdanmark AS (TOP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Tompkins Financial Corp (TMP):企業の財務・戦略的SWOT分析
    Tompkins Financial Corp (TMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆